Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE

Nature Reviews Clinical Oncology, Published online: 06 July 2023; doi:10.1038/s41571-023-00797-4Planning for a pregnancy in patients receiving adjuvant endocrine therapy following a diagnosis of hormone receptor (HR)-positive early stage breast cancer is challenging. Recent data from the POSITIVE trial provide reassuring prospective evidence that a temporary interruption of endocrine therapy for women with HR-positive breast cancer who are trying to conceive can be considered safe in the short term for selected patients.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research